Epigenetics Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Genome Integrity Unit, Children's Medical Research Institute, University of Sydney, Westmead, NSW, 2145, Australia.
Clin Epigenetics. 2021 Feb 17;13(1):37. doi: 10.1186/s13148-021-01023-7.
BRG1 (encoded by SMARCA4) is a catalytic component of the SWI/SNF chromatin remodelling complex, with key roles in modulating DNA accessibility. Dysregulation of BRG1 is observed, but functionally uncharacterised, in a wide range of malignancies. We have probed the functions of BRG1 on a background of prostate cancer to investigate how BRG1 controls gene expression programmes and cancer cell behaviour.
Our investigation of SMARCA4 revealed that BRG1 is over-expressed in the majority of the 486 tumours from The Cancer Genome Atlas prostate cohort, as well as in a complementary panel of 21 prostate cell lines. Next, we utilised a temporal model of BRG1 depletion to investigate the molecular effects on global transcription programmes. Depleting BRG1 had no impact on alternative splicing and conferred only modest effect on global expression. However, of the transcriptional changes that occurred, most manifested as down-regulated expression. Deeper examination found the common thread linking down-regulated genes was involvement in proliferation, including several known to increase prostate cancer proliferation (KLK2, PCAT1 and VAV3). Interestingly, the promoters of genes driving proliferation were bound by BRG1 as well as the transcription factors, AR and FOXA1. We also noted that BRG1 depletion repressed genes involved in cell cycle progression and DNA replication, but intriguingly, these pathways operated independently of AR and FOXA1. In agreement with transcriptional changes, depleting BRG1 conferred G1 arrest.
Our data have revealed that BRG1 promotes cell cycle progression and DNA replication, consistent with the increased cell proliferation associated with oncogenesis.
BRG1(由 SMARCA4 编码)是 SWI/SNF 染色质重塑复合物的催化亚基,在调节 DNA 可及性方面发挥着关键作用。在广泛的恶性肿瘤中观察到 BRG1 的失调,但功能尚未得到充分表征。我们在前列腺癌的背景下研究了 BRG1 的功能,以研究 BRG1 如何控制基因表达程序和癌细胞行为。
我们对 SMARCA4 的研究表明,BRG1 在癌症基因组图谱前列腺队列的 486 个肿瘤中的大多数以及 21 个前列腺细胞系的互补面板中过表达。接下来,我们利用 BRG1 耗竭的时间模型来研究对全局转录程序的分子影响。BRG1 的耗竭对可变剪接没有影响,对全局表达只有适度的影响。然而,发生的转录变化大多数表现为下调表达。更深入的研究发现,连接下调基因的共同线索是参与增殖,包括几个已知增加前列腺癌增殖的基因(KLK2、PCAT1 和 VAV3)。有趣的是,驱动增殖的基因的启动子被 BRG1 以及转录因子 AR 和 FOXA1 结合。我们还注意到,BRG1 耗竭抑制了参与细胞周期进程和 DNA 复制的基因,但有趣的是,这些途径独立于 AR 和 FOXA1 运作。与转录变化一致,BRG1 的耗竭导致 G1 期停滞。
我们的数据揭示了 BRG1 促进细胞周期进程和 DNA 复制,与致癌相关的细胞增殖增加一致。